Update shared on06 Aug 2025
Fair value Decreased 6.31%Despite an upward revision in revenue growth forecasts, Neogen Chemicals’ consensus price target has been lowered to ₹2,062, primarily due to a substantial decline in its future P/E multiple.
What's in the News
- Annual dividend decreased to INR 1 per share for FY 2024-25.
- Incorporated wholly owned subsidiary “Neogen Morita New Materials Limited” to pursue lithium-ion battery material opportunities, facilitating a potential joint venture with Morita Chemicals Industries (Japan).
- Temporarily suspended production at Dahej SEZ Multi-Purpose Plant (MPP3) due to fire; received total insurance claim of INR 800 million; reconstruction estimated to take 9-12 months, with some production shifted to other sites to minimize business disruption.
- Upcoming board meeting to consider and approve Q1 FY26 financial results.
- Board considering proposal to raise funds via issuance of non-convertible debentures.
Valuation Changes
Summary of Valuation Changes for Neogen Chemicals
- The Consensus Analyst Price Target has fallen from ₹2200 to ₹2062.
- The Future P/E for Neogen Chemicals has significantly fallen from 54.99x to 42.32x.
- The Consensus Revenue Growth forecasts for Neogen Chemicals has risen from 47.0% per annum to 50.2% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.